
Diagnosis, Risk Stratification, And Management Of Pulmonary Hypertension Of Sickle Cell Disease.
Key Points
Key Points
Observational studies have consistently shown that increased tricuspid regurgitant jet velocity (TRV) measured by Doppler echocardiography, an increased serum N-terminal pro–brain natriuretic peptide (NT-pro-BNP) level, and pulmonary hypertension measured by right heart catheterization are all independent risk factors for mortality in adults.
To reduce the variability and to improve the quality of care that patients with SCD receive, the ATS developed clinical practice guidelines to advise hematologists, pulmonologists, cardiologists, pediatricians, and internists about how to identify and manage patients with SCD who are at increased risk for mortality.
Diagnosis
...Diagnosis...
...atification guides clinical decision making in SCD...
...eased risk for mortality is defined a...
...e Questions for Evaluation of Dyspne...
...osed Algorithm for Evaluation of Pulmon...
...re 2. Echocardiogram of a Patient with P...
Treatment
...Treatment...
...th SCD who have an increased risk...
...ients with SCD who have an increased risk for mort...
...ith SCD who have RHC-confirmed PH, venous thromb...
...all patients with SCD who have elevated TRV alone...
...most patients with SCD who have RHC-con...
...ct patients with SCD who have RHC-confirmed ma...
...h SCD who have RHC-confirmed marked elevation of t...
...edications Class/Agent Dose...